Tetramine-Based Hyperbranched Polyimide Membranes with Rigid Crosslinker for Improved Gas Permeability and Stability.

Triamine-based HBPI membranes are known for high gas separation selectivity and physical stability, but their permeabilities are still very low. In this study, we utilized a tetramine monomer called TPDA (N,N,N',N'-tetrakis(4-aminophenyl)-1,4-benzenediamine) as a crosslinking center and incorporated an additional diamine comonomer called DAM (2,4,6-trimethyl-1,3-diaminobenzene) to enhance gas separation performance, especially gas permeability. The findings demonstrated that the resultant 6FDA-DAM/TPDA membranes based on tetramine TPDA exhibited a greater amount of free volume compared to the triamine-based HBPI membranes, resulting in significantly higher gas permeabilities.

Locking the Spiro Carbon in Spirobisindane Using Sulfur and Phosphorus to Form "Olympic Ring"-like Molecules.

To improve the rigidity of spirobisindane, it was intramolecularly locked by forming eight-membered rings via sulfur and phosphorus atoms to produce an interlocked polycyclic structure under mild conditions in good yields. By carefully analyzing the crystal structures, we noticed that the angle between the two benzene rings in the locked version is significantly smaller than that of the typical spirobisindane structure. Molecular modeling indicated that locking the spiro center can remarkably enhance the rigidity.

Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes.

Peroxisome proliferator-activated receptor γ (PPARγ) is recognized as a key regulator of insulin resistance. In this study, we searched for novel PPARγ agonists in a library of structurally diverse organic compounds and determined that podophyllotoxin exhibits partial agonist activity toward PPARγ. Eight novel podophyllotoxin-like derivatives were synthesized and assayed for toxicity and functional activity toward PPARγ to reduce the possible systemic toxic effects of podophyllotoxin and to maintain partial agonist activity toward PPARγ.